Company Information

    Alkahest was founded on January 2014. The company is based in San Carlos, CA, USA . The number of employees in Alkahest is less than 50. Alkahest s mission is to enrich the health and vitality of humankind through transformative therapies that counterbalance the aging process.
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Alkahest has received 3 rounds of venture funding. The total funding amount is around $41M.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Alkahest - Blog

                          • Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer

                          • SAN CARLOS, Calif., July 28, 2021 — Alkahest, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced the appointment of Dr. César Cerezo M.D., Ph.D., as chief medical officer. He will be responsible for leading and providing strategic direction to the […]The post Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer appeared first on Alkahest.
                          • Cesar Cerezo

                          • Cesar Cerezo is an experienced pharmaceutical industry leader with extensive and significant contributions to the advancement of clinical development programs across different therapeutic areas. Prior to his position at Alkahest, Dr. Cerezo served as Vice President and Therapeutic Area Head of Global Medical Affairs General Medicine at Amgen. In this role, he led the development […]The post Cesar Cerezo appeared first on Alkahest.
                          • Esther Rawner

                          • Esther has 15 years of experience in clinical medicine and leadership roles driving advancements across a wide range of disease areas including neurologic, ophthalmologic and dermatologic conditions. Immediately before joining Alkahest she served as Medical Director of Stroke at the University of Washington NW Hospital and Regional Medical Director at Neurotech NW, merging effective medical […]The post Esther Rawner appeared first on Alkahest.
                          • Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s Disease

                          • SAN CARLOS, Calif., March 08, 2021 (GLOBE NEWSWIRE) — Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced it will be delivering a presentation of data from a completed study of its therapeutic plasma fraction candidate, GRF6021, in subjects […]The post Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s Disease appeared first on Alkahest.
                          • Jessica Powell

                          • Jessica has over 20 years of experience in academic and pharmaceutical research and operations management. Jessica leads the Clinical Operations team at Alkahest and is responsible for developing and implementing the clinical operations strategy and overseeing the execution of clinical studies across Alkahest’s pipeline. Jessica has managed programs from pre-IND through Phase 3 clinical trials […]The post Jessica Powell appeared first on Alkahest.
                          • Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome

                          • Grifols to acquire remaining stock of Alkahest, Inc. in exchange for a total price of $146 million, on a debt-free basis, bringing its ownership of Alkahest to 100%; the transaction is expected to close in early 2021 Alkahest currently has four candidates in six phase-2 clinical trials covering therapeutic products for neurodegenerative, cognitive decline, neuromuscular […]The post Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome appeared first on Alkahest.

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *